BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,406,928 | +1330.6% | 167,119 | +799.5% | 0.03% | +1033.3% |
Q1 2023 | $308,039 | -68.2% | 18,579 | -80.9% | 0.00% | -62.5% |
Q3 2022 | $970,000 | -39.7% | 97,519 | -44.9% | 0.01% | -50.0% |
Q2 2022 | $1,608,000 | -26.7% | 177,026 | -18.2% | 0.02% | -20.0% |
Q1 2022 | $2,195,000 | -19.2% | 216,300 | +32.8% | 0.02% | -20.0% |
Q4 2021 | $2,717,000 | +218.5% | 162,900 | +795.1% | 0.02% | +177.8% |
Q3 2021 | $853,000 | -70.2% | 18,200 | -61.2% | 0.01% | -70.0% |
Q2 2021 | $2,858,000 | +2.8% | 46,887 | +3.9% | 0.03% | -11.8% |
Q1 2021 | $2,780,000 | +337.8% | 45,137 | +405.7% | 0.03% | +277.8% |
Q4 2020 | $635,000 | -28.7% | 8,926 | -62.4% | 0.01% | -47.1% |
Q3 2020 | $890,000 | +2.1% | 23,741 | -11.1% | 0.02% | +41.7% |
Q2 2020 | $872,000 | – | 26,692 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |